CytoMed Therapeutics Ltd GDTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.92
- Day Range
- $0.84–0.92
- 52-Week Range
- $0.00–3.10
- Bid/Ask
- $0.84 / $0.94
- Shares Outstanding
- 11.93M
- Market Cap
- $10.97M
- Volume/Avg
- 4,847 / 77,652
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 42.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 42
- Website
- https://w2.cytomed.sg
Valuation
|
Metric
|
GDTC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.85 |
Price/Sales | 42.81 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GDTC
|
|---|---|
Quick Ratio | 1.51 |
Current Ratio | 2.64 |
Interest Coverage | −172.25 |
Quick Ratio
GDTC
Profitability
|
Metric
|
GDTC
|
|---|---|
Return on Assets (Normalized) | −48.22% |
Return on Equity (Normalized) | −62.21% |
Return on Invested Capital (Normalized) | −52.52% |
Return on Assets
GDTC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>s<kG@ | LOCK|Nk$^ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!tW#&>& | LOCK|$$Xm | $83B | |||
| Moderna Inc
MRNA
| LOCK|&QdJ!< | LOCK|q?B | $80B | |||
| argenx SE ADR
ARGX
| LOCK|PvJkBy | LOCK|z$ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?KBw$@ | LOCK|H! | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!yG!pyK | LOCK|%>l% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|P&%^qD? | LOCK|VN$&< | $28B | |||
| Incyte Corp
INCY
| LOCK|^<&T$g | LOCK|$Nh | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|ySF@Br | LOCK|L^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@!N>&R | LOCK|PM% | $14B |
United States